Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
US FDA unveils new pathway to approve personalized therapies - 2DEA seizes 1.7 million counterfeit fentanyl pills in Colorado storage unit
- 3Rescuers give up hope for the humpback whale stranded in the Baltic Sea
- 4People are getting their news from AI – and it’s altering their views
- 5Architect Frank Gehry has died: See his most iconic buildings
- Picking Childcare Administrations for Your Loved ones
- Inside Plan with Houseplants: An Aide
- Netanyahu vows to ‘return Negev to Israel,’ pledges settlement growth during visit
- Artemis 2 astronauts arrive at Kennedy Space Center ahead of NASA's historic launch around the moon
- The Most Astonishing Arising Advances to Watch
- The most effective method to Boost Benefits in Gold Speculation: Master Techniques and Tips
- NASA's Artemis 2 astronauts are cruising to the moon. So why are they doing CPR tests today?
- The Delight of Camper Vans: Choosing the One That Meets Your Requirements
- Earthquake in Indonesia kills at least 1 person and sets off small tsunami
